Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?

Pro: Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?

Date

11 Sep 2022

Session

Stage III NSCLC: What defines resectability in the era of neoadjuvant chemo-IO v. PACIFIC?

Topics

Multi-Disciplinary and Multi-Professional Cancer Care;  Immunotherapy;  Radiation Oncology;  Surgical Oncology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Jonathan Spicer

Authors

J. Spicer

Author affiliations

  • McGill University, H3A 1X1 - Montreal/CA

Resources

This content is available to ESMO members and event participants.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.